Immunotherapy against several tumors, such as lung cancer, including NSCLC
A method of treating a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma. A method of treating a patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the NSCLC, lung cancer, gastric cancer, and/or glioblastoma.
1. A method of eliciting an immune response in a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, and/or gastric cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of KIQEMQHFL (SEQ ID NO: 2), wherein the peptide is in a complex with an MHC molecule, and wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.
2. The method of claim 1 , wherein the T cells are autologous to the patient.
3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.
4. The method of claim 1 , wherein the T cells are derived from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1 , further comprising expanding T cells in vitro.
6. The method of claim 1 , wherein the MHC molecule is a class I molecule.
7. The method of claim 1 , wherein the composition further comprises an adjuvant.
8. The method of claim 7 , wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSP, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG-containing oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG) and virosomes.
9. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.
10. The method of claim 9 , wherein the antigen presenting cell is a dendritic cell or a macrophage.
11. The method of claim 1 , further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells.
12. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.